Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

International Nursing Organizations I01:23

International Nursing Organizations I

2.2K
International Nursing Organization (ICN) is a global union of national nurses' organizations. Individual nurses can be a part of ICN through member organizations. Each member organization strives to ensure quality nursing care, sound health policies, the advancement of nursing knowledge, respect for the profession, and a satisfied and competent nursing workforce.
ICN member organizations work to advance the field of nursing and healthcare via policies, partnerships, lobbying, professional...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Barriers: Active Packaging Strategies for Sustainable Food Protection.

Polymers·2026
Same author

Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study.

Therapeutic advances in hematology·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026
Same author

Zein-based polysaccharide-tannic acid films as multifunctional barriers to prevent post-surgical adhesions.

International journal of pharmaceutics: X·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026
Same author

Prognostic Significance of Erythrocyte Sedimentation Rate for Survival in Equine Colic.

Animals : an open access journal from MDPI·2026

Related Experiment Video

Updated: May 1, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 24, 2014

140.3K

ITP and international guidelines: what do we know, what do we need?

Francesco Rodeghiero1, Marco Ruggeri1

  • 1San Bortolo Hospital, Department of Cell Therapy and Hematology, 36100 Vicenza, Italy.

Presse Medicale (Paris, France : 1983)
|March 25, 2014
PubMed
Summary

New treatments like rituximab and TPO-receptor agonists (TPO-ra) offer alternatives for Immune Thrombocytopenia (ITP). Guidelines differ on their use versus splenectomy, highlighting the need for personalized ITP management.

More Related Videos

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

38.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Related Experiment Videos

Last Updated: May 1, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 24, 2014

140.3K
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

38.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Immune Thrombocytopenia (ITP) management traditionally involves corticosteroids and splenectomy.
  • Recent decades introduced rituximab and thrombopoietin-receptor agonists (TPO-ra) as therapeutic options.
  • Two major international guidelines (ICR and ASH) now incorporate these advancements.

Purpose of the Study:

  • To analyze the current international guidelines for Immune Thrombocytopenia (ITP) treatment.
  • To compare the recommendations regarding corticosteroids, TPO-receptor agonists (TPO-ra), rituximab, and splenectomy.
  • To identify areas of agreement and disagreement in ITP management strategies.

Main Methods:

  • Comparative analysis of two international guidelines: International Consensus Report (ICR) and American Society of Hematology (ASH).
  • Review of treatment approaches for newly diagnosed, persistent, and chronic ITP phases.
  • Evaluation of first, second, and third-line treatment strategies.

Main Results:

  • Substantial agreement exists on initial corticosteroid use and TPO-ra as a third-line option post-splenectomy.
  • Inconsistent recommendations regarding second-line treatments: ICR places rituximab and TPO-ra alongside splenectomy, while ASH reserves them for post-splenectomy or contraindications.
  • Standardized ITP terminology and disease phasing are now adopted.

Conclusions:

  • Discrepancies between guidelines necessitate careful consideration of individual patient factors in ITP management.
  • Further research is needed on long-term outcomes, toxicity of TPO-ra and rituximab, and thrombotic risk in ITP.
  • Personalized treatment tailoring based on clinical outcomes, not just platelet count, is crucial for optimal ITP care.